Two Houston-based companies made it into this new clean tech accelerator. Photo via greentownlabs.com

The Low-Carbon Hydrogen Accelerator announced its inaugural class of clean tech startups — two of which hail from right here in Hosuton.

In all, seven startups have been chosen to participate this year in the Low-Carbon Hydrogen Accelerator, which was announced in November. The six-month accelerator program offers collaboration and engagement opportunities with the Electric Power Research Institute and its member utilities, as well as with Shell. Through the accelerator, the institute and Shell will provide startups with two innovation paths: a technology validation track and a technology demonstration track.

The accelerator — part of the Green Go program, affiliated with Greentown Labs — is aimed at coming up with innovations in low-carbon hydrogen production, storage, and distribution.

“Accelerating low-carbon hydrogen technologies is an essential part of achieving global net-zero targets by 2050,” Neva Espinoza, vice president of energy supply and low-carbon resources at the Electric Power Research Institute, says in a news release.

The inaugural LCHA cohort includes:

  • Advanced Ionics, based in Milwaukee, is enabling green hydrogen production without the green premium.
  • Arco Technologies from Bologna, Italy, is developing a proprietary Anion Exchange Membrane electrolyzer with the lowest capital expenditures and operating expenses possible today.
  • Based in Manchester in the United Kingdom, Clean Power is developing a novel, low-cost, highly durable hydrogen polymer electrolyte membrane fuel cell delivering zero-emission electricity.
  • Element Resources, based in Houston, is enabling compressed hydrogen storage tank technology.
  • Another local company, Smartpipe Technologies is developing a robust self-monitored repurposed pipeline system for hydrogen with minimal environmental disruption.
  • SPEC Sensors from California is creating a robust and reliable meshed sensor network for hydrogen leak detection and line-monitoring systems.
  • Canadian company RUNWITHIT Synthetics is creating a live, digital twin modeling platform that generates decision-support data for regional hydrogen-demand scenarios.

Element Resources, which produces hydrogen from renewables for mobility, power production, and energy storage, is collaborating with Zhifeng Ren, M.D. Anderson chair professor in physics and director of the Texas Center for Superconductivity at the University of Houston.

The other Houston startup, Smartpipe Technologies, announced earlier this month that Canadian pipeline company Enbridge had made a $6.6 million investment in the startup.

For 2022, the accelerator received applications from 88 startups in 18 countries. The five other participants this year are from California; Wisconsin; Alberta, Canada; Italy; and the United Kingdom.

Aside from the Electric Power Research Institute, Shell USA, and Greentown, the accelerator’s partners are the City of Houston and the Urban Future Lab at New York University’s Tandon School of Engineering.

“Creating a robust hydrogen economy will require a systems-oriented approach and unparalleled cooperation between corporate partners and emerging companies,” says Ryan Dings, chief operating officer and general counsel at Greentown Labs.

Greentown operates startup incubators in Somerville, Massachusetts, and Houston.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.